MarketBeat
15 Aug 2026, 09:02 UTC · 3h ago
Madrigal's Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
15 Aug 2026, 09:02 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Madrigal reported Q2 2026 revenue of $364 million, a 71% year-over-year increase, with a trailing-12-month run rate of approximately $1.3 billion. — Strong top-line growth and a billion-dollar run rate validate the commercial viability of Rezdiffra and suggest a 'mega blockbuster' trajectory.
+0.80Successful outcomes in the ongoing MAESTRO-NASH Outcomes study for F4 disease could potentially double Rezdiffra's addressable market. — Expanding the indication to include approximately 245,000 F4 compensated-cirrhosis patients represents a massive increase in total addressable market (TAM).
+0.70Madrigal reports that Novo Nordisk's Wegovy has had no significant negative impact on Rezdiffra sales, noting less than 1% of Wegovy prescriptions are written by specialists for MASH. — This mitigates fears that GLP-1 agonists would cannibalize the market for liver-specific therapies in the short term.
+0.50Continue reading
6 related stories
Search tags
The company has expanded its pipeline to 10 assets, including a GLP-1 agonist (MGL-2086) and a DGAT-2 inhibitor, intended for combination use with Rezdiffra. — Diversification into combination therapies creates long-term value and potential for synergistic efficacy, though most are in early stages.
+0.40European sales are expected to remain negligible in 2026 due to reimbursement hurdles and U.S. administration policy uncertainties. — Delayed international revenue streams act as a drag on the company's immediate global growth potential.
-0.30Which stocks this story touches
Reported strong commercial growth for Rezdiffra, a 71% revenue increase, and a positive outlook for its development pipeline.
Mentioned as a competitor with Wegovy, but Madrigal states it has not had a significant negative impact on their sales.
Mentioned as the company that licensed ervogastat to Madrigal, with no material financial impact reported.
Mentioned as the company that licensed an siRNA targeting PNPLA3 to Madrigal.
[a_to_b] Madrigal licensed the asset ervogastat from Pfizer.
[a_to_b] Madrigal licensed an siRNA targeting PNPLA3 from Arrowhead Pharmaceuticals.
[mutual] Madrigal's Rezdiffra competes with Novo Nordisk's Wegovy in the MASH market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
19h ago
